Berrueco Rubén

Dr. Berrueco Rubén

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2018 in Platelets
Verified
Journal Article
Closed access
NRNuria Revilla
Nuria Revilla
JCJavier Corral
Javier Corral
AMAntonia Miñano
Antonia Miñano
MMMaría Eva Mingot-Castellano
María Eva Mingot-Castellano
RCRosa Maria Campos
Rosa Maria Campos
MLMaria L Lozano
Maria L Lozano
Patients with multirefractory immune thrombocytopenia (ITP) have limited treatment options. Recent data suggest that specific anti-platelet antibodies may cause destruction of platelets by favoring platelet loss of sialic acid. In this multicenter study 35 patients with ITP, including 16 with multirefractory disease, were analyzed for antiplatelet-antibodies, thrombopoietin (TPO) levels, and platelet desialylation. In selected cases, responses to a novel treatment strategy using oseltamivir were tested. We found that antibodies against GPIbα were overrepresented in multirefractory patients compared to responders (n = 19). In contrast to conventional ITP patients, multirefractory patients exhibited a significant increased platelet activation state (granule secretion) and desialylation (RCA-1 binding) (p < 0.05), and a trend toward higher plasma TPO concentrations. The decreased sialic acid content seemed to be restricted to platelet glycoproteins, since other plasma proteins were not hypoglycosylated. A total of 10 patients with multirefractory ITP having remarkable loss of platelet terminal sialic acids were given oseltamivir phosphate. When the antiviral drug was combined with TPO receptor agonists (TPO-RAs) or with immunosuppressant drugs, platelet responses were observed in 66.7% of patients. All responding patients presented with antibodies reactive only against GPIbα. These findings suggest that desialylation may play a key pathogenic role in some multirefractory ITP patients, and provide diagnostic tools for the identification of such patients. Furthermore, we show that sialidase inhibitor treatment in combination with therapies that help to increase platelet production can induce sustained platelet responses in some patients with anti-GPIbα -mediated thrombocytopenia that have failed previous therapies.

29 September 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
NBNina Borràs
Nina Borràs
JBJavier Batlle
Javier Batlle
APAlmudena Pérez-Rodríguez
Almudena Pérez-Rodríguez
MLMaría Fernanda López-Fernández
María Fernanda López-Fernández
ÁRÁngela Rodríguez-Trillo
Ángela Rodríguez-Trillo
ICIrene Corrales
Irene Corrales
Molecular diagnosis of patients with von Willebrand disease is pending in most populations due to the complexity and high cost of conventional molecular analyses. The need for molecular and clinical characterization of von Willebrand disease in Spain prompted the creation of a multicenter project (PCM-EVW-ES) that resulted in the largest prospective cohort study of patients with all types of von Willebrand disease. Molecular analysis of relevant regions of the VWF, including intronic and promoter regions, was achieved in the 556 individuals recruited via the development of a simple, innovative, relatively low-cost protocol based on microfluidic technology and next-generation sequencing. A total of 704 variants (237 different) were identified along VWF, 155 of which had not been previously recorded in the international mutation database. The potential pathogenic effect of these variants was assessed by in silico analysis. Furthermore, four short tandem repeats were analyzed in order to evaluate the ancestral origin of recurrent mutations. The outcome of genetic analysis allowed for the reclassification of 110 patients, identification of 37 asymptomatic carriers (important for genetic counseling) and re-inclusion of 43 patients previously excluded by phenotyping results. In total, 480 patients were definitively diagnosed. Candidate mutations were identified in all patients except 13 type 1 von Willebrand disease, yielding a high genotype-phenotype correlation. Our data reinforce the capital importance and usefulness of genetics in von Willebrand disease diagnostics. The progressive implementation of molecular study as the first-line test for routine diagnosis of this condition will lead to increasingly more personalized and effective care for this patient population.

2 November 2016 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ECElena Cela
Elena Cela
JBJosé M. Bellón
José M. Bellón
MCMaría de la Cruz
María de la Cruz
CBCristina Belendez
Cristina Belendez
BRBerrueco Rubén
Berrueco Rubén
OPon behalf of the SEHOP-Hemoglobinopathies Study Group (Sociedad Española de Hematología y Oncología Pediátricas)
on behalf of the SEHOP-Hemoglobinopathies Study Group (Sociedad Española de Hematología y Oncología Pediátricas)

20 May 2010 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CLCristian Launes
Cristian Launes
SRSusana Rives
Susana Rives
ACAlbert Català
Albert Català
BRBerrueco Rubén
Berrueco Rubén
TTTeresa Toll
Teresa Toll
JEJesús Estella
Jesús Estella

15 March 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
ARAnna Ruiz-Llobet
Anna Ruiz-Llobet
SRSusanna Gassiot Riu
Susanna Gassiot Riu
ESEdurne Sarrate
Edurne Sarrate
JZJosune Zubicaray
Josune Zubicaray
JDJosé Luis Dapena
José Luis Dapena
BRBerrueco Rubén
Berrueco Rubén

1 July 2013 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
BRBerrueco Rubén
Berrueco Rubén
SRSusana Rives
Susana Rives
ACAlbert Català
Albert Català
TTTeresa Toll
Teresa Toll
AGAmadeu Gene
Amadeu Gene
MUMireya Urrea
Mireya Urrea
The use of intensive chemotherapy and central devices has improved patients survival, but it is associated with catheter-related blood-stream infections (CRBSI). An educational program was instituted for preventing CRBSI occurrence in acute leukemia pediatric patients having totally implanted central devices. The Centers of Disease Control and Prevention criteria were used as definition for CRBSI. Data collected were age, sex, diagnosis, chemotherapy, inpatient versus outpatient, microbiological data, risk factors, social risk score, and treatment performed. CRBSI rate decreased from 6.7 to 3.7/1000 catheter-days with preventive measures (P=0.05). A further decrease to 1.5/1000 catheter-days was reached after the intensification of the educational program (P=0.01). Severe neutropenia at the time of catheter insertion was related to CRBSI and to infection recurrence (P<0.05). Most of the episodes occurred during induction chemotherapy. Thirty-six CRBSI episodes occurred in 25 of 73 patients. The most frequent microorganism isolated was Staphylococcus spp. Antibiotherapy was successful in 83.3% of episodes. Six patients needed a central venous access device replacement. Our intervention program was successful to decrease the CRBSI rates and its intensification allowed a further decrease, approaching reported rates in this setting. Severe neutropenia at the time of central venous access device insertion was related to CRBSI occurrence and recurrence.